Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has approved...